...
首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Race/ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy
【24h】

Race/ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy

机译:接受溶栓治疗的缺血性中风患者出血并发症风险的种族/种族差异

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE - : Race/ethnic-related differences in safety of intravenous thrombolytic therapy have been shown in patients with myocardial infarction, but not studied in ischemic stroke. METHODS - : Using data from the Get With The Guidelines (GWTG)-Stroke program (n=54 334), we evaluated differences in risk-adjusted bleeding rates (any, symptomatic intracerebral hemorrhage [sICH], serious life-threatening [excluding sICH], or other) and mortality in white (n=40 411), black (n=8243), Hispanic (n=4257), and Asian (n=1523) patients receiving intravenous tissue-type plasminogen activator (tPA) for acute ischemic stroke. RESULTS - : Compared with white patients, overall adjusted hemorrhagic complications after tPA were higher in black (odds ratio, 1.14, 95% confidence interval, 1.04-1.28) and Asian (odds ratio, 1.36, 95% confidence interval, 1.14-1.61) patients. Overall adjusted bleeding complications in Hispanics were similar to those of whites. Increased risk of overall bleeding in Asians was related to higher risk of adjusted sICH (odds ratio, 1.47, 95% confidence interval, 1.19-1.82), whereas in blacks, it was related to higher risk of other bleeding. No significant race-related difference was noted in risk of serious or life-threatening bleeding or in overall mortality or death in patients with sICH or any hemorrhagic complications. CONCLUSIONS - : In patients with stroke receiving tPA, hemorrhagic complications were slightly higher in blacks and Asians, but not in Hispanics compared with whites. Asians also faced significantly higher risk for sICH relative to other race/ethnic groups. Future studies are needed to evaluate whether reduction in tPA dose similar to that used in many Asian countries could improve the safety of tPA therapy in Asians in the United States with acute ischemic strokes while maintaining efficacy.
机译:背景和目的-:在心肌梗死患者中已经显示出种族/种族相关的静脉溶栓治疗安全性差异,但尚未在缺血性卒中中进行研究。方法-:使用来自“获得指导方针(GWTG)-中风”计划(n = 54 334)的数据,我们评估了风险调整后的出血率(任何,有症状的脑出血[sICH],严重威胁生命的[sICH除外])的差异]或其他)和接受静脉注射组织型纤溶酶原激活剂(tPA)的白人(n = 40411),黑人(n = 8243),西班牙裔(n = 4257)和亚洲人(n = 1523)的死亡率缺血性中风。结果-:与白人患者相比,tPA术后总体调整后的出血并发症在黑人(赔率,1.14,95%置信区间,1.04-1.28)和亚洲人(赔率,1.36,95%置信区间,1.14-1.61)方面更高耐心。西班牙裔的总体调整后出血并发症与白人相似。亚洲人总体出血的风险增加与调整后的sICH的风险较高相关(比值比为1.47,95%置信区间为1.19-1.82),而在黑人中,其与其他出血风险较高相关。 sICH或任何出血性并发症患者发生严重或危及生命的出血风险或总体死亡率或死亡风险方面,未发现与种族有关的显着差异。结论-:在接受tPA的中风患者中,黑人和亚洲人的出血并发症略高,而西班牙人与白人相比则没有。与其他种族/族裔群体相比,亚洲人也面临着sICH的更高风险。需要进行进一步的研究来评估减少tPA剂量是否类似于许多亚洲国家所使用的剂量,是否可以提高急性缺血性中风的美国亚洲人tPA治疗的安全性,同时保持疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号